China Cell Reprogramming Market Size & Outlook, 2023-2030
China cell reprogramming market, 2018-2030 (US$M)
Related Markets
China cell reprogramming market highlights
- The China cell reprogramming market generated a revenue of USD 19.5 million in 2023 and is expected to reach USD 39.3 million by 2030.
- The China market is expected to grow at a CAGR of 10.6% from 2024 to 2030.
- In terms of segment, episomal reprogramming was the largest revenue generating technology in 2023.
- MRNA Reprogramming is the most lucrative technology segment registering the fastest growth during the forecast period.
Cell reprogramming market data book summary
| Market revenue in 2023 | USD 19.5 million |
| Market revenue in 2030 | USD 39.3 million |
| Growth rate | 10.6% (CAGR from 2023 to 2030) |
| Largest segment | Episomal reprogramming |
| Fastest growing segment | MRNA Reprogramming |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Sendai Virus-based Reprogramming, MRNA Reprogramming, Episomal Reprogramming |
| Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Techne Corp, ReproCELL, Lonza Group Ltd, FUJIFILM Holdings Corp, Astellas Pharma Inc, Allele Biotech, Alstem, STEMCELL Technologies |
Other key industry trends
- In terms of revenue, China accounted for 5.2% of the global cell reprogramming market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China cell reprogramming market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 39.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Reprogramming Market Scope
Cell Reprogramming Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China cell reprogramming market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell reprogramming market will help companies and investors design strategic landscapes.
Episomal reprogramming was the largest segment with a revenue share of 31.79% in 2023. Horizon Databook has segmented the China cell reprogramming market based on sendai virus-based reprogramming, mrna reprogramming, episomal reprogramming covering the revenue growth of each sub-segment from 2018 to 2030.
For instance, the Chinese Academy of Sciences, Beijing Institute for Stem Cell and Regenerative Medicine, and the Institute of Zoology/Institute for Stem Cell and Regeneration announced an event, Pluripotent Stem Cell Conference (PS Conf 2023), in October 2023, building on the success of the previous PS Conf meetings in 2021 and 2022.
The discussions will focus on experiences with stem cell-derived organoids and products, accompanied by training sessions on biobanking and discussions addressing ethical and quality considerations in hPSC-derived organoids.
The Bridging Session will facilitate dialogue between Chinese and international scientific networks, fostering global collaboration on advancing stem cell standards and shaping future priorities. Such initiatives are expected to drive market growth.
Reasons to subscribe to China cell reprogramming market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China cell reprogramming market databook
-
Our clientele includes a mix of cell reprogramming market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China cell reprogramming market , including forecasts for subscribers. This country databook contains high-level insights into China cell reprogramming market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China cell reprogramming market size, by technology, 2018-2030 (US$M)
China Cell Reprogramming Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
